One year in review 2015: Idiopathic inflammatory myopathies

Clinical and Experimental Rheumatology

Volumn 33, Issue 5, 2015, Pages 593-601

  Barsotti, Simone ^a   Terenzi, Riccardo ^b   La Paglia, Giuliana M C ^b   Bellucci, Eleonora ^c   Baldini, Chiara ^a   Neri, Rossella ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Biomarkers; Clinical manifestations; Dermatomyositis; Idiopathic inflammatory myopathies; Imaging; Pathogenesis; Polymyositis; Therapy

Indexed keywords

ADALIMUMAB; BETA INTERFERON; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; HIGH MOBILITY GROUP B1 PROTEIN; HLA DRB1 ANTIGEN; IMMUNOGLOBULIN G; INTERLEUKIN 22; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PAMIDRONIC ACID; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SODIUM THIOSULFATE; TACROLIMUS; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; AUTACOID; IMMUNOLOGIC FACTOR;

ADAPTIVE IMMUNITY; AEROBIC EXERCISE; ANTIGEN EXPRESSION; APOPTOSIS; AUTOIMMUNITY; B LYMPHOCYTE; CALCIUM HOMEOSTASIS; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CLINICAL FEATURE; CYTOKINE RELEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG PULSE THERAPY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; ELECTROMYOGRAPHY; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; MEDICAL HISTORY; MUSCLE BIOPSY; MUSCLE WEAKNESS; MYOSITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SARCOPLASMIC RETICULUM; SKIN CALCIFICATION; TREATMENT DURATION; TREATMENT INDICATION; UPREGULATION; ANIMAL; IMMUNOLOGY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; TREATMENT OUTCOME;

ANIMALS; ANTIRHEUMATIC AGENTS; AUTOIMMUNITY; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION MEDIATORS; MUSCLE, SKELETAL; MYOSITIS; PREDICTIVE VALUE OF TESTS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84944402311     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. GAO X, HAN L, YUAN L et al.: HLA class II alleles may influence susceptibility to adult dermatomyositis and polymyositis in a Han Chinese population. BMC Dermatol 2014; 14: 9.
2. SUGIURA T, KAWAGUCHI Y, GOTO K et al.: Association between a C8orf13-BLK polymorphism and polymyositis/dermatomyositis in the Japanese population: an additive effect with STAT4 on disease susceptibility. PloS One 2014; 9: e90019.
3. MILLER FW, COOPER RG, VENCOVSKỲ J et al.: Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. Arthritis Rheum 2013; 65: 3239-47.
4. GüTTSCHES A-K, JACOBSEN F, THEISS C et al.: Human β-defensin-3 correlates with muscle fibre degeneration in idiopathic inflammatory myopathies. Innate Immun 2014; 20: 49-60.
5. SUáREZ-CALVET X, GALLARDO E, NOGALES-GADEA G et al.: Altered RIG-I/DDX58-mediated innate immunity in dermatomyositis. J Pathol 2014; 233: 258-68.
6. GIROLAMO F, LIA A, AMATI A et al.: Overexpression of autophagic proteins in the skeletal muscle of sporadic inclusion body myositis. Neuropathol Appl Neurobiol 2013; 39: 736-49.
7. NOGALSKA A, D'AGOSTINO C, ENGEL WK, ASKANAS V: Sodium phenylbutyrate reverses lysosomal dysfunction and decreases amyloid-β42 in an in vitro-model of inclusion-body myositis. Neurobiol Dis 2014; 65: 93-101.
8. FRéRET M, DROUOT L, OBRY A et al.: Overexpression of MHC class I in muscle of lymphocyte-deficient mice causes a severe myopathy with induction of the unfolded protein response. Am J Pathol 2013; 183: 893-904.
9. De PAEPE B, De BLEECKER JL: The nonnecrotic invaded muscle fibers of polymyositis and sporadic inclusion body myositis: on the interplay of chemokines and stress proteins. Neurosci Lett 2013; 535: 18-23.
10. ZONG M, BRUTON JD, GRUNDTMAN C et al.: TLR4 as receptor for HMGB1 induced muscle dysfunction in myositis. Ann Rheum Dis 2013; 72: 1390-9.
11. McINTYRE D, ZUCKERMAN NS, FIELD M, MEHR R, STOTT DI: The V(H) repertoire and clonal diversification of B cells in inflammatory myopathies. Eur J Immunol 2014; 44: 585-96.
12. LóPEZ De PADILLA CM, McNALLAN KT, CROWSON CS et al.: BAFF expression correlates with idiopathic inflammatory myopathy disease activity measures and autoantibodies. J Rheumatol 2013; 40: 294-302.
13. TANG X, TIAN X, ZHANG Y et al.: Correlation between the frequency of Th17 cell and the expression of microRNA-206 in patients with dermatomyositis. Clin Dev Immunol 2013; 2013: 345-7.
14. ALLENBACH Y, CHAARA W, ROSENZWAJG M et al.: Th1 response and systemic treg deficiency in inclusion body myositis. PloS One 2014; 9: e887-88.
15. GEORGANTAS RW, STREICHER K, GREENBERG SA et al.: Inhibition of myogenic microRNAs 1, 133, and 206 by inflammatory cytokines links inflammation and muscle degeneration in adult inflammatory myopathies. Arthritis Rheumatol 2014; 66: 1022-33.
16. YANG M, CEN X, XIE Q, ZUO C, SHI G, YIN G: Serum interleukin-6 expression level and its clinical significance in patients with dermatomyositis. Clin Dev Immunol 2013; 2013: 717-808.
17. CICCIA F, RIZZO A, ALESSANDRO R et al.: Activated IL-22 pathway occurs in the muscle tissues of patients with polymyositis or dermatomyositis and is correlated with disease activity. Rheumatology (Oxford) 2014; 53: 1307-12.
18. LINKLATER H, PIPITONE N, ROSE MR et al.: Classifying idiopathic inflammatory myopathies: comparing the performance of six existing criteria. Clin Exp Rheumatol 2013; 31: 767-9.
19. LUNDBERG IE: New classification criteria for idiopathic inflammatory myopathies. First international Conference on Myositis 8-11 May 2015 Stockholm Sweden.
20. LUO Y-B, MASTAGLIA FL: Dermatomyositis, polymyositis and immune-mediated necrotising myopathies. Biochim Biophys Acta 2015; 1852: 622-32.
21. ALLENBACH Y, DROUOT L, RIGOLET A et al.: Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine (Baltimore) 2014; 93: 150-7.
22. NICHOLS L, PFEIFER K, MAMMEN AL, SHAHNOOR N, KONERSMAN CG: An Unusual Case of Statin-Induced Myopathy: AntiHMGCoA Necrotizing Autoimmune Myopathy. J Gen Intern Med 2015 Apr 9;
23. CRUELLAS MGP, VIANA V Dos ST, LEVY-NETO M, SOUZA FHC De, SHINJO SK: Myositisspecific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis. Clin São Paulo Braz 2013; 68: 909-14.
24. RINNENTHAL JL, GOEBEL H-H, PREUSSE C et al.: Inflammatory myopathy with abundant macrophages (IMAM): the immunology revisited. Neuromuscul Disord 2014; 24: 151-5.
25. HAMANN PDH, COOPER RG, McHUGH NJ, CHINOY H: Statin-induced necrotizing myositis-a discrete autoimmune entity within the "statin-induced myopathy spectrum." Autoimmun Rev 2013; 12: 1177-81.
26. WANG H, LIU H-X, WANG Y-L, YU X-Q, CHEN X-X, CAI L: Left ventricular diastolic dysfunction in patients with dermatomyositis without clinically evident cardiovascular disease. J Rheumatol 2014; 41: 495-500.
27. LU Z, WEI Q, NING Z, QIAN-ZI Z, XIAO-MING S, GUO-CHUN W: Left ventricular diastolic dysfunction-early cardiac impairment in patients with polymyositis/dermatomyositis: a tissue Doppler imaging study. J Rheumatol. 2013; 40: 1572-7.
28. De SOUZA FHC, SHINJO SK: The high prevalence of metabolic syndrome in polymyositis. Clin Exp Rheumatol 2014; 32: 82-7.
29. COUVRAT-DESVERGNES G, MASSEAU A, BENVENISTE O et al.: The spectrum of renal involvement in patients with inflammatory myopathies. Medicine (Baltimore) 2014; 93: 33-41.
30. BRADY S, SQUIER W, HILTON-JONES D: Clinical assessment determines the diagnosis of inclusion body myositis independently of pathological features. J Neurol Neurosurg Psychiatry 2013; 84: 1240-6.
31. ALEXANDERSON H, Del GRANDE M, BINGHAM CO 3rD et al.: Patient-reported Outcomes and Adult Patients' Disease Experience in the Idiopathic Inflammatory Myopathies. Report from the OMERACT 11 Myositis Special Interest Group. J Rheumatol 2014; 41: 581-92.
32. GHIRARDELLO A, BORELLA E, BEGGIO M, FRANCESCHINI F, FREDI M, DORIA A: Myositis autoantibodies and clinical phenotypes. Auto-Immun Highlights 2014; 5: 69-75.
33. FERNANDEZ C, BARDIN N, De PAULA AM et al.: Correlation of clinicoserologic and pathologic classifications of inflammatory myopathies: study of 178 cases and guidelines for diagnosis. Medicine (Baltimore) 2013; 92: 15-24.
34. De BLEECKER JL, De PAEPE B, ARONICA E et al.: 205th ENMC International Workshop: Pathology diagnosis of idiopathic inflamma-tory myopathies part II 28-30 March 2014, Naarden, The Netherlands. Neuromuscul Disord 2015; 25: 268-72.
35. TROYANOV Y, TARGOFF IN, PAYETTE MP et al.: Redefining dermatomyositis: a description of new diagnostic criteria that differentiate pure dermatomyositis from overlap myositis with dermatomyositis features. Medicine (Baltimore) 2014; 93: 318-32.
36. LABRADOR-HORRILLO M, MARTINEZ MA, SELVA-O'CALLAGHAN A et al.: Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis. J Immunol Res 2014; 2014: 290797.
37. CHEN Z, CAO M, PLANA MN et al.: Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis Care Res 2013; 65: 1316-24.
38. SATO S, KUWANA M, FUJITA T, SUZUKI Y: Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol 2013; 23: 496-502.
39. CERIBELLI A, FREDI M, TARABORELLI M et al.: Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis. Clin Exp Rheumatol 2014; 32: 891-7.
40. VALENZUELA A, CHUNG L, CASCIOLA-ROSEN L, FIORENTINO D: Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis. JAMA Dermatol 2014; 150: 724-9.
41. FIORENTINO DF, CHUNG LS, CHRISTOPHERSTINE L et al.: Most patients with cancerassociated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1?. Arthritis Rheum 2013; 65: 2954-62.
42. FUJIMOTO M, MATSUSHITA T, HAMAGUCHI Y et al.: Autoantibodies to small ubiquitinlike modifier activating enzymes in Japanese patients with dermatomyositis: comparison with a UK Caucasian cohort. Ann Rheum Dis 2013; 72: 151-3.
43. LABRADOR-HORRILLO M, MARTíNEZ MA, SELVA-O'CALLAGHAN A et al.: Identification of a novel myositis-associated antibody directed against cortactin. Autoimmun Rev 2014; 13: 1008-12.
44. MARIE I, JOSSE S, DECAUX O et al.: Clinical manifestations and outcome of anti-PL7 positive patients with antisynthetase syndrome. Eur J Intern Med 2013; 24: 474-9.
45. HAMAGUCHI Y, FUJIMOTO M, MATSUSHITA T et al.: Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PloS One 2013; 8: e60442.
46. LARMAN HB, SALAJEGHEH M, NAZARENO R et al.: Cytosolic 5'-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol 2013; 73: 408-18.
47. GREENBERG SA: Cytoplasmic 5'-nucleotidase autoantibodies in inclusion body myositis: Isotypes and diagnostic utility. Muscle Nerve 2014; 50: 488-92.
48. PLUK H, van HOEVE BJA, van DOOREN SHJ et al.: Autoantibodies to cytosolic 5'-nucleotidase 1A in inclusion body myositis. Ann Neurol 2013; 73: 397-407.
49. YAO L, GAI N: Fat-corrected T2 measurement as a marker of active muscle disease in inflammatory myopathy. AJR Am J Roentgenol 2012; 198: W475-81.
50. PIPITONE N, VERSARI A, ZUCCOLI G et al.: 18F-Fluorodeoxyglucose positron emission tomography for the assessment of myositis: a case series. Clin Exp Rheumatol 2012; 30: 570-3.
51. CAVAGNA L, CAPORALI R, ABDÌ-ALÌ L, DORE R, MELONI F, MONTECUCCO C: Cyclosporine in anti-Jo1-positive patients with corticosteroid-refractory interstitial lung disease. J Rheumatol 2013; 40: 484-92.
52. LABIRUA-ITURBURU A, SELVA-O'CALLAGHAN A, MARTíNEZ-GóMEZ X, TRALLERO-ARAGUáS E, LABRADOR-HORRILLO M, VILARDELL-TARRéS M: Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease. Clin Exp Rheumatol 2013; 31: 436-9.
53. De VITA S, NERI R, BOMBARDIERI S: Cyclophosphamide pulses in the treatment of rheumatic diseases: an update. Clin Exp Rheumatol 1991; 9: 179-93.
54. NAGAPPA M, TALY AB, SINHA S et al.: Efficacy and limitations of pulse cyclophosphamide therapy in polymyositis and dermatomyositis. J Clin Neuromuscul Dis 2013; 14: 161-8.
55. SUZUKI A, SHOJI N, KIKUCHI E et al.: Successful combination therapy with corticosteroids, biweekly intravenous pulse cyclophosphamide and cyclosporin A for acute interstitial pneumonia in patients with dermatomyositis: report of three cases. Nihon Rinsho Meneki Gakkai Kaishi 2013; 36: 122-8.
56. ODDIS CV, REED AM, AGGARWAL R et al.: Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013; 65: 314-24.
57. De VISSER M: Editorial: The efficacy of rituximab in refractory myositis: The jury is still out. Arthritis Rheum 2013; 65: 303-6.
58. BOHAN A, PETER JB: Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-7.
59. CUTTNER J, SPIERA H, GOREVIC P: Rituximab in refractory and relapsed dermatomyositis and polymyositis: comment on the article by Oddis et al. Arthritis Rheum 2013; 65: 2497-8.
60. MUñOZ-BEAMUD F, ISENBERG DA: Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies. Clin Exp Rheumatol 2013; 31: 896-903.
61. NALOTTO L, IACCARINO L, ZEN M et al.: Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature. Immunol Res 2013; 56: 362-70.
62. SáNCHEZ-FERNáNDEZ Sá, CARRASCO FERNáNDEZ JA, ROJAS VARGAS LM: Efficacy of rituximab in dermatomyositis and polymyositis refractory to conventional therapy. Reumatol Clin 2013; 9: 117-9.
63. UNGER L, KAMPF S, LüTHKE K, ARINGER M: Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population. Rheumatology (Oxford) 2014; 53: 1630-8.
64. AGGARWAL R, BANDOS A, REED AM et al.: Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol 2014; 66: 740-9.
65. HASSAN AB, NIKITINA-ZAKE L, SANJEEVI CB, LUNDBERG IE, PADYUKOV L: Association of the proinflammatory haplotype (MICA5.1/TNF2/TNFa2/DRB1*03) with polymyositis and dermatomyositis. Arthritis Rheum 2004; 50: 1013-5.
66. CHEN D, WANG X, ZHOU Y, ZHU X: Efficacy of infliximab in the treatment for dermatomyositis with acute interstitial pneumonia: a study of fourteen cases and literature review. Rheumatol Int 2013; 33: 2455-8.
67. ROUSTER-STEVENS KA, FERGUSON L, MORGAN G, HUANG C-C, PACHMAN LM: Pilot study of etanercept in patients with refractory juvenile dermatomyositis. Arthritis Care Res 2014; 66: 783-7.
68. Da SILVA TCP, ZON PRETTI F, SHINJO SK: Adalimumab in anti-synthetase syndrome. Joint Bone Spine 2013; 80: 432.
69. MARIE I: Therapy of polymyositis and dermatomyositis. Presse Med 2011:40: e257-e270.
70. GRUNDTMAN C, SALOMONSSON S, DORPH C, BRUTON J, ANDERSSON U, LUNDBERG IE: Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in patients with idiopathic inflammatory myopathies. Arthritis Rheum 2007; 56: 674-87.
71. ENGLUND P, NENNESMO I, KLARESKOG L, LUNDBERG IE: Interleukin-1alpha expression in capillaries and major histocompatibility complex class I expression in type II muscle fibers from polymyositis and dermatomyositis patients: important pathogenic features independent of inflammatory cell clusters in muscle tissue. Arthritis Rheum 2002; 46: 1044-55.
72. LINDVALL B, DAHLBOM K, HENRIKSSON KG, SRINIVAS U, ERNERUDH J: The expression of adhesion molecules in muscle biopsies: the LFA-1/VLA-4 ratio in polymyositis. Acta Neurol Scand 2003; 107: 134-41.
73. ZONG M, DORPH C, DASTMALCHI M et al.: Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up. Ann Rheum Dis 2014; 73: 913-20.
74. KOSMIDIS ML, ALEXOPOULOS H, TZIOUFAS AG, DALAKAS MC: The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot study. J Neurol Sci 2013; 334: 123-5.
75. KEROLA AM, KAUPPI MJ: Abatacept as a successful theraphy for myositis-a case based review. Clin Rheumatol 2015; 34: 609-12.
76. KALY L, ROSNER I: Tocilizumab-A novel therapy for non-organ-specific autoimmune diseases. Best Pract Res Clin Rheumatol 2012; 26: 157-65.
77. DALAKAS MC: Mechanistic effects of IVIg in neuroinflammatory diseases: conclusions based on clinicopathologic correlations. J Clin Immunol 2014; 34 (Suppl. 1): S120-6.
78. DALAKAS MC: Immunotherapy of Inflam-matory Myopathies: pratical approach and future prospects. Curr Treat Options Neurol 2011; 13: 311-23.
79. PATWA HS, CHAUDHRY V, KATZBERG H, RAEGRANT AD, SO YT: Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2012; 78: 1009-15.
80. WANG DX, SHU XM, TIAN XL et al.: Intravenous immunoglobulin therapy in adult patients with polymyositis/dermatomyositis: a systematic literature review. Clin Rheumatol 2012; 31: 801-6.
81. FEMIA AN, EASTHAM AB, LAM C, MEROLA JF, QURESHI AA, VLEUGELS RA: Intravenous immunoglobulin for refractory cutaneous dermatomyositis: a retrospective analysis from an academic medical center. J Am Acad Dermatol 2013; 69: 654-7.
82. DANIELI MG, PETTINARI L, MORETTI R, LOGULLO F, GABRIELLI A: Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. Autoimmun Rev 2011; 10: 144-9.
83. PARS K, GARDE N, SKRIPULETZ T, PUL R, DENGLER R, STANGEL M: Subcutaneous immunoglobulin treatment of inclusion-body myositis stabilizes dysphagia. Muscle Nerve 2013; 48: 838-9.
84. GELARDI C, PAOLINI L, DANIELI MG: Subcutaneous immunoglobulin G in idiopathic inflammatory myopathies: therapeutic implications. Isr Med Assoc J 2014; 16: 646-7.
85. KILMER DD, McCRORY MA, WRIGHT NC, AITKENS SG, BERNAUER EM: The effect of a high resistance exercise program in slowly progressive neuromuscular disease. Arch Phys Med Rehabil 1994; 75: 560-3.
86. VOET NBM, van Der KOOI EL, RIPHAGEN II, LINDEMAN E, van ENGELEN BGM, GEURTS ACH: Strength training and aerobic exercise training for muscle disease. Cochrane Database Syst Rev 2013; 7: CD003907.
87. WIESINGER GF, QUITTAN M, GRANINGER M et al.: Benefit of 6 months long-term physical training in polymyositis/dermatomyositis patients. Br J Rheumatol 1998; 37: 1338-42.
88. ALEMO MUNTERS L, DASTMALCHI M, ANDGREN V et al.: Improvement in health and possible reduction in disease activity using endurance exercise in patients with established polymyositis and dermatomyositis: a multicenter randomized controlled trial with a 1-year open extension followup. Arthritis Care Res (Hoboken) 2013; 65: 1959-68.
89. ALEMO MUNTERS L, ALEXANDERSON H, CROFFORD LJ, LUNDBERG IE: New insights into the benefits of exercise for muscle health in patients with idiopathic inflammatory myositis. Curr Rheumatol Rep 2014; 16: 429.
90. CHANDER S, GORDON P: Soft tissue and subcutaneous calcification in connective tissue diseases. Curr Opin Rheumatol 2012; 24: 158-64.
91. PAGNINI I, SIMONINI G, GIANI T et al.: Sodium thiosulfate for the treatment of calcinosis secondary to juvenile dermatomyositis. Clin Exp Rheumatol 2014; 32: 408-9.
92. MARTILLOTTI J, MOOTE D, ZEMEL L: Improvement of calcinosis using pamidronate in a patient with juvenile dermatomyositis. Pediatr Radiol 2014; 44: 115-8.
93. TERROSO G, BERNARDES M, ALEIXO A et al.: Therapy of calcinosis universalis complicating adult dermatomyositis. Acta Reumatol Port 2013; 38: 44-8.